Insurance: health insurers; coverage for antineoplastic drugs; expand. Amends sec. 3406e of 1956 PA 218 (MCL 500.3406e).

This bill requires health insurance companies in Michigan to cover specific cancer drugs, including genetic therapies and immunotherapies like CAR-T cell therapy, even when used for purposes not originally approved by the FDA. Coverage is mandated for any FDA-approved drug used in cancer treatment if a physician orders it based on current medical evidence, the drug is part of a standard cancer regimen, and the patient provides informed consent for the off-label use. The law ensures that insurers must pay for the medication and its reasonable administration costs under these conditions, regardless of whether the specific cancer being treated matches the drug's initial FDA approval. This change directly affects patients seeking advanced cancer treatments and the insurance providers that must now include these therapies in their policies.